Preferred Label : Serplulimab;
NCIt definition : A humanized monoclonal antibody directed against the negative immunoregulatory human
cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab
targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may
restore immune function through the activation of T-cells and T-cell-mediated immune
responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin
superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively
regulates T-cell activation and effector function when activated by its ligands programmed
cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion
from host immunity.;
UNII : S3GQZ2K36V;
CAS number : 2231029-82-4;
Molecule name : HLX-10; HLX 10;
NCI Metathesaurus CUI : CL935905;
Codes from synonyms : 35064;
Origin ID : C156738;
UMLS CUI : C5418260;
Currated CISMeF NLP mapping
Semantic type(s)
UMLS correspondences (same concept)
chemical_or_drug_has_mechanism_of_action
concept_is_in_subset
has_target
https://www.ema.europa.eu/en/medicines/human/EPAR/hetronifly
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Serplulimab
Serplulimab
drug approval
europe
antibodies, monoclonal
antibodies, monoclonal
serplulimab
small cell lung carcinoma
neoplasm metastasis
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
carboplatin
etoposide
infusions, intravenous
programmed cell death 1 receptor
risk management
product surveillance, postmarketing
Extensive Stage Lung Small Cell Carcinoma
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical
---